Point-Of-Care Manufacturing Successfully Treats B-Cell Cancers; How Will FDA Regulate It?

In Cleveland and Moscow, researchers found freshly-manufactured T-cells showed faster reduction of tumor burden than cryopreserved cells, but uncertainty remains about what the clearance process for the technology will be at the US FDA.